PRPO
Precipio, Inc. NASDAQ Listed Jun 30, 2017$30.40
Mkt Cap $54.2M
52w Low $5.94
88.3% of range
52w High $33.63
50d MA $27.48
200d MA $22.11
P/E (TTM)
-134.5x
EV/EBITDA
23.6x
P/B
3.4x
Debt/Equity
0.2x
ROE
-2.5%
P/FCF
102.7x
RSI (14)
—
ATR (14)
—
Beta
1.20
50d MA
$27.48
200d MA
$22.11
Avg Volume
25.9K
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
4 Science Park · New Haven, CT 06511 · US
Data updated apr 26, 2026 8:49pm
· Source: massive.com